MEDIA ADVISORY --- BIO 2001: Highlight of Events for Wednesday, June 27

  • Recommend
  • Tweet
  • Print
  • Email
7 - 8:00 a.m.
Plenary Breakfast
Ballroom 6
2001 Biotechnology Heritage
Award
, presented to Dr. Francis S. Collins, Director of the Human Genome
Institute at NIH and Dr. J. Craig Venter, Celera Genomics Corporation. (Note:
Collins and Venter will be available to the media immediately following
the breakfast in room 5B.)

 

8:15 - 9:45 a.m.

Food and Ag Track Session
Upper Level, Room 2
The Global Trade Dilemma,
led by Paul Drazek, President, DTB Associates, panel speakers will discuss
how increasingly expensive regulations impede international trade, largely
between developing countries. Speakers will review the current impacts of
trade, including costs and barriers. (Note: Panelists will be available
to the media immediately following the track session in room 5B.)

 

8:15 - 9:45 a.m.

CommunicationsMezzanine Level, Room 16B
Biotech in the Media -
How Are We Doing?
, chaired by Dan Eramian, Vice President, Communications,
Biotechnology Industry Organization, a panel of reporters who cover the
biotechnology industry will discuss the effectiveness of the industry in
presenting itself and its case to the public with regards to the announcement
of the Human Genome Project, the introduction of GMO crops and foods and
the prescription drug debate, among other issues.

 

10:15 - 11:45 a.m.

Food and Ag Track Session
Upper Level, Room 2
Lack of Global Harmonization
and Challenges for Developing Countries
, chaired by L. Val Giddings,
Vice President, Food and Agriculture, Biotechnology Industry Organization,
academics from the U.S. and Africa address the impact of agricultural biotechnology
for developing countries.

 

11 a.m.

Press Conference
Upper Level, Room 5B
Israeli Export Institute:
The Israeli Chief Scientist of the Israeli Ministry of Trade and Compugen
Ltd.
, will give an overview of the biotechnology industry in Israel.

 

12 - 1:45 p.m.

Plenary LuncheonBallroom 6
Naomi Judd, Grammy award-winning
singer, and Alan Hobson, cancer survivor and Mt. Everest climber
(Note:
Judd and Hobson will be available to the media immediately following in
room 5B.)

 

2- 3:30 p.m.

Industrial and Environmental Track Session

Upper Level, Room 3
Global Climate Change and
Energy - Can Modern Biotechnology Provide Workable Solutions?
, led by
James S. McLaren, Ph.D., President, Inverizon International Inc., speakers
will discuss the broad-ranging positive impacts that industrial biotechnology
solutions can have on issues pertaining to our environment.

 

2- 3:30 p.m.

Policy/Ethics Track Session

UMezzanine Level, 16A
Conserving Endangered Species
in the Genomics Era
, this session brings scientists working at the interface
of genomics and conservation from the world-famous San Diego Zoo, the biotechnology
industry and the Human Genome Project to present new research findings and
initiatives for benefiting endangered species. Chaired by Oliver A. Ryder,
Ph.D., Kleberg Genetics Chair, Center for Reproduction of Endangered Species.

 

2 - 3:30 p.m.

Science Track Session

Upper Level, Room 9
Hitting the Target - Accurate
Drug Delivery
, the panel of speakers, led by Paul Drayson, Ph.D., CEO.
PowerJect Pharmaceuticals plc, has been chosen to provide a broad overview
of the current  state of the art  in biotech drug delivery and will provide
thoughtful, provocative insights into the challenges and opportunities ahead
for the industry.

 

2 - 3:30 p.m.

Science Track Session

Upper Level, Room 10
Regenerative Medicine: Sustaining
Human Health by Harnessing the Body's Regenerative Capabilities
, Co-chairs
Doros Platika, M.D., President and CEO, Curtis, Inc. and Daniel Hartmann,
Faculty of Pharmacy, will discuss how regenerative medicine seeks to harness
the body's inherent ability to repair damage caused by disease, trauma or
age.

 

3:30 p.m.

Press Conference

Upper Level, Room 5B

Biotechnology Industry Organization and Ardana Bioscience to Donate
$30,000 Grant to World-Famous San Diego Zoo
, presented to Dr. Oliver
A. Ryder, Kleberg Genetics Chair, Center for Reproduction of Endangered
Species, by Simon G. Best, Chief Executive Officer, Ardana Bioscience,
Board of Directors, Biotechnology Industry Organization; David Robinson,
Chairman, Biotechnology Industry Organization, Chairman, President and
Chief Executive Officer, Ligand Pharmaceuticals, Inc.; Joe Panetta, President
and Chief Executive Officer, BIOCOM/san diego and Ray Briscuso, Executive
Director, Biotechnology Industry Organization.

 

4 - 5:30 p.m.

IP/Legal Track Session

Upper Level, Room 4

Global Balancing Act: Intellectual
Property Rights and the Plight of the Poor
, Anne G. K. Solomon, Senior
Adviser and Former Deputy Assistant Secretary of State for Science, Technology
and Health, will lead a discussion about intellectual property rights (IPR)
protection and its importance to the vitality of technological innovation
and commercialization.

 

4 - 5:30 p.m.

Policy/Ethics

Mezzanine Level, Room 16A

Cloning and Stem Cells:
New Controversies
, led by Michael J. Werner, Esq., Director, Federal
Government Relations/Bioethics Counsel, Biotechnology Industry Organization,
this session will examine the NIH policy to allow federal funding for research
using stem cells, which is currently under review by the Bush administration.

 

4 - 5:30 p.m.

Science Track Session

Upper Level, Room 9

Innovative Research and Infectious
Diseases, a panel led by Gerald Yakatan, Ph.D., President and CEO, Avanir
Pharmaceuticals, will discuss some of the cutting-edge research that could
lead to treatments for infectious diseases such as hepatitis, herpes, malaria,
HIV and the common cold.

 

2 - 3:30 p.m.

Therapeutic Devices Track Session

Mezzanine Level, Room 14A

The Future of DNA Microarrays
and Bioinformatics in Research and Diagnostics
, chaired by August Sick,
Senior Manager, Business Development, Invitrogen Corporation, this session
will present recent applications demonstrating the power of microarrays
and advanced bioinformatics technologies in identifying differentially expressed
biomarker genes.

 

2 - 3:30 p.m.

Policy/Ethics Session

Mezzanine Level, Room 16A

Oversight of Gene Therapy:
Protecting Patients and Promoting Research


The FDA and NIH have recently formally issued plans that would dramatically
change the regulatory environment for companies doing gene therapy experiments.
This program, chaired by Michael J. Werner, Esq., Director, Federal Government
Relations/Bioethics Counsel, Biotechnology Industry Organization, will discuss
several important issues surrounding regulation in the industry.

 

2 - 5:30 p.m.

Finance Track Session

Upper Level, Room 11

Mergers & Acquisitions
Symposium
, chaired by Richard A. Leavitt, Principal, William Gallagher
Associates Insurance Brokers, Inc., and Stephen Ferruolo, Shareholder, Heller
Ehrman White & McAuliffe LLP, speakers on this panel will address the
future of genomics and the information challenge it poses.

 

3 p.m.

Press Conference

Upper Level, Room 5B

Florence Wambugu, Ph.D.,
Director, ISSA AfriCenter, Kenya, will discuss her book, "Modifying
Africa: How Biotechnology Can Benfit the Poor and Hungry: A Case Study from
Kenya."

 

4 p.m.

Press Conference

Upper Level, Room 5B

MediChem/Neurocrine Announcement,
MediChem (NASDAQ:MCLS) a Chicago-based drug discovery technology and services
company, and Neurocrine Biosciences (NASDAQ: NBIX), a San Diego-based biopharmaceutical
discovery and development company, will announce that they have entered
into a two-year collaborative GPCR agreement in proteomics for new drug
development.

 

4 - 5:30 p.m.

Science Track Session

pper Level, Room 9

Animal, Mineral or Vegetable:
Which Model for Product Discovery
, John A. Ryals, Ph.D., President and
CEO, Paradigm Genetics, chairs a discussion about the utility of different
gene-based discovery models that have influenced the success of the genomics
industry.

 

4 - 5:30 p.m.

Policy/Ethics Track Session

Mezzanine Level, Room 16A

The Impact of State Drug
Price Control Schemes on Emerging Biotech Companies
, Thomas C. Norton,
Senior Vice President, SPECTRUM Science Public Relations, chairs a discussion
of the consequences of state drug price control programs.

 

4 - 5:30 p.m.

Therapeutic Devices Track Session

Mezzanine Level, Room 14A

Managing Diabetes: Advances
in Insulin Therapy from Novel Delivery Systems
, Lars Karlsen, Senior
Vice President, Head of Project Portfolio Managements, Novo Nordisk A/S,
chairs a discussion of how recent advances in insulin delivery will improve
patient compliance with insulin regimens and quality of life.

 

4 - 5:30 p.m.

Science Track Session

Upper Level, Room 10

Raiders of the Lost Genome:
Gene Analysis on the Post-Genome Era
, chaired by Teresa W. Ayers, CEO
and Director, Genomica, this panel will review and discuss a variety of
new technologies that will facilitate the deciphering of genetic data and
provide gene function information for product development.

 

4 - 5:30 p.m.

Food and Ag Track Session

Upper Level, Room 2

Innovative Research and
Infectious Diseases
, a panel led by Gerald Yakatan, Ph.D., President
and CEO, Avanir Pharmaceuticals, will discuss some of the cutting-edge research
that could lead to treatments for infectious diseases such as hepatitis,
herpes, malaria, HIV and the common cold.

 

4 - 5:30 p.m.

Science Track Session

Upper Level, Room 10

Stopping Global Pandemics
in the Track
, chaired by Franklin Berger, Senior Analyst, JP Morgan.

 


About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.